
MZT Holdings Inc (AKA: Matritech Inc) Profile last edited on: 6/12/19
CAGE:
UEI:
Business Identifier: NO Business Identifier is currently available for this company. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Multiple
Congr. District: 04
County: Middlesex
Congr. District: 04
County: Middlesex
Public Profile
In September 2007, Matritech Inc was acquired by Inverness Medical Innovations, Inc. Matritech Inc. develops, manufactures and markets innovative cancer diagnostic products based on its proprietary nuclear matrix protein (NMP) technology. The nuclear matrix, a three dimensional protein framework within the nucleus of cells, plays a fundamental role in determining cell type by physically organizing the contents of the nucleus, including DNA. The Company has demonstrated that there are differences in the types and amounts of NMPs found in cancerous and normal tissue and believes the detection of such differences in NMPs provides important diagnostic information about cellular abnormalities, including cancer. Using its proprietary NMP technology and expertise, the Company has developed non-invasive or minimally invasive cancer diagnostic tests for bladder and colon cancer and is developing additional tests for cervical, breast and prostate cancer. Close ties to Massachusetts Institute of Technology (MIT) and Johns Hopkins University School of Medicine.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
75-99Revenue Range
7.5M-10MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : MZTHIP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
1998 | 1 | NIH | $78,000 | |
Project Title: Numa Protein Complexes As Unique Tumor Markers | ||||
1995 | 1 | NIH | $99,731 | |
Project Title: Drug Screening Assay for Novel Chemotherapeutic Agents | ||||
1995 | 1 | NIH | $99,358 | |
Project Title: Nuclear Matrix Proteins CC 4/CC-5--Colon Cancer Markers | ||||
1995 | 1 | NIH | $88,003 | |
Project Title: High Specificity Therapeutic Agent for Prostate Cancer | ||||
1994 | 1 | NIH | $75,000 | |
Project Title: Nuclear matrix protein PC-1 - marker for prostate cancer |
Key People / Management
Stephen D Chubb -- CEO
Joseph V Briggman
Edward G Fey
Susan Keesee
Gregory Thill
Joseph V Briggman
Edward G Fey
Susan Keesee
Gregory Thill
Company News
There are no news available.